Singapore, Oct. 29 -- Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, on 28 October 2019, announced that the completion of a placement of ten million new fully paid ordinary shares in the Company to institutional, professional, and sophisticated investors in Australia and internationally, at a price of A$0.40 per New Share (Institutional Placement). The Institutional Placement will raise A$4.0 million (exclusive of costs).

Key Points

Oversubscribed Institutional Placement led by multiple high-quality institutional investors in Australia and Asia

Company has capitalised on recent appreciation in share price, driven by emerging data from broad-based clinical trial programs, and has substantially strength...